Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Sarcoma 5Sarcoma, Kaposi 4Unspecified Adult Solid Tumor, Protocol Specific 3Skin Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 2Prostatic Neoplasms 2Head and Neck Neoplasms 2HIV Infections 2Colonic Neoplasms 2AIDS-related Kaposi sarcoma 2Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Solitary Fibrous Tumor, Pleural 1Salivary Gland Neoplasms 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Oligodendroglioma 1Neoplasms, Unknown Primary 1Neoplasms, Plasma Cell 1Nasopharyngeal Neoplasms 1Multiple Myeloma 1Mesothelioma, Malignant 1Meningioma 1Melanoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Kidney Neoplasms 1Inflammatory Breast Neoplasms 1

Interventions

Temozolomide 45Radiotherapy 16Carboplatin 15Irinotecan 12Carmustine 12Bevacizumab 12Filgrastim 10Vincristine 9Surgical Procedures, Operative 9Magnetic Resonance Spectroscopy 9Procarbazine 7Peripheral Blood Stem Cell Transplantation 6Imatinib Mesylate 6Erlotinib Hydrochloride 6temsirolimus 5sargramostim 5O(6)-benzylguanine 5Lomustine 5Flucytosine 5Etoposide 5Thiotepa 4Sirolimus 4Cyclophosphamide 4aldesleukin 3Thalidomide 3Surveys and Questionnaires 3Sunitinib 3Radiotherapy, Intensity-Modulated 3Radiation 3Polymerase Chain Reaction 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Oligodendroglioma × Semaxinib × Clear all
NCT00004868 2018-06-27

SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Completed
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Meningioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡